This website uses cookies. By using the site you are agreeing to our Privacy Policy.

HOME >> Investor Relations >> Top Message >> Message Archive (April 1, 2011 )


To all of our investors - April 1, 2011 -

The new fiscal year has arrived, and for the benefit of our shareholders and investors, I would like to report on some trends in the industry and on the recent situation at Japan Tissue Engineering (J-TEC).

Dealing with the Great Tohoku Earthquake

I wish to extend my deepest condolences to the bereaved families of those who tragically perished due to the terrible earthquake that occurred on March 11. I offer my heartfelt prayers for the victims and their families.
What J-TEC can do to help might be limited, but in cooperation with the Ministry of Health, Labor and Welfare, government agencies and industrial organizations, we intend to do whatever we can to aid the afflicted and help the affected region to recover.

Contributing to the Medical Innovation Promotion Office

The Medical Innovation Promotion Office was established within the Cabinet Secretariat in January 2011 in order to achieve “life innovation,” which is a pillar of Japan’s new growth strategy. From a perspective that extends from the short term to the long term, this office aims to investigate the forms that medical treatment should take in the future and create new growth industries that will propel the economy forward, while at the same time reflecting the results of those efforts in the medical treatment that people receive. Specifically, six working teams will be formed and propose policies for the achievement of those objectives. The working teams are: (1) Drugs and Medicines, (2) Medical Equipment, (3) Regenerative Medicine, (4) Individualized Medicine, (5) Intellectual Property and (6) Regulatory Science.
J-TEC intends to participate in the activities that some of these working teams undertake. Particularly in the field of regenerative medicine, where J-TEC is the only company in Japan that is actually developing, manufacturing and selling products and that therefore understands, first-hand, the problems and issues involved in establishing regenerative medicine as a new industry, we hope to offer forward-looking proposals and contribute to the advancement of medical care and economic progress in Japan.

Symbiosis with DebRA Japan

On March 18, 2011, our company’s JACE product was officially designated as a medical device for rare diseases suitable for the treatment of epidermolysis bullosa. As a result, J-TEC will begin preparations for clinical trials aimed at expanding the use of JACE in treating this disorder.
In 2009, J-TEC began selling JACE as a medical device, covered by insurance, for the treatment of severe burns. However, we have for a long time conducted investigations focused on expanding the use of JACE to the treatment of other ailments for which it is assumed to be effective. Through obtaining guidance from specialists in epidermolysis bullosa as well as from the Ministry of Health, Labor and Welfare, we have finally been able to clear the first hurdle toward the achievement of that goal.
The Friends of Epidermolysis Bullosa (known as DebRA Japan), a patient group in Japan, was founded in 2007. In March 2011, representatives from DebRA Japan, including its president, Ms. Keiko Miyamoto, visited J-TEC. As a result, DebRA Japan and J-TEC have formed a kind of symbiotic relationship that augurs great benefits for both of us.

April 1, 2011
Yosuke Ozawa
President & CEO
Japan Tissue Engineering Co., Ltd.

in J-TEC headquarters

DebRA Japan’s Ms. Keiko Miyamoto (president), Mr. Mitsuru Miyamoto (executive office director), Ms. Takako Susukida (Kanto branch office representative), and J-TEC employees